BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  People

  For Alltrna CEO Michelle Werner, Making Better Drugs Is Personal

  Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.

  March 31, 2025

   · 

  5 min read

   · 

  Shawna Williams
• 

  Radiopharmaceuticals

  5 Big Pharmas Push Boundaries in Radiopharmaceuticals

  While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.

  March 31, 2025

   · 

  9 min read

   · 

  Tristan Manalac
• 

  IN PARTNERSHIP WITH ECLIPSEBIO

  Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development
  

  AI offers tremendous potential but there are critical and time-consuming flaws in black box AI predictions.

  March 31, 2025

   · 

  7 min read

   · 

  BioSpace Insights
• 

  IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES

  Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges

  Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.

  March 31, 2025

   · 

  5 min read

   · 

  BioSpace Insights
• 

  Regulatory

  FDA Action Alert: Amgen, Aldeyra and Argenx

  In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

  March 31, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• Press Releases

  European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

  March 31, 2025

   · 

  6 min read
• Press Releases

  International Medication Systems, Ltd. Receives FDA’s Drug Shortage Assistance Award

  March 31, 2025

   · 

  5 min read
• Press Releases

  FDA Issues Complete Response Letter for Etripamil for PSVT

  March 31, 2025

   · 

  5 min read
• Press Releases

  TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

  March 31, 2025

   · 

  13 min read
• Press Releases

  FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

  March 31, 2025

   · 

  8 min read